Market Research Logo

The World Market for Neurotherapeutic Drugs


Attention: There is an updated edition available for this report.

Neurotherapeutics for non-psychiatric disorders present what may be the greatest field of unmet need in medicine. They have been significantly underdiagnosed and vastly underserved for a number of reasons. Certain neurological disorders, such as peripheral neuropathies, are secondary to other conditions, which overshadow the neuropathy. In addition, CNS conditions are frequently undiagnosed or unrecognized because their symptoms may not cause sufficient concern in the patient or may be confused with those of other conditions by the clinician. As a result, the incidence and prevalence of the CNS diseases and disorders that are not seriously debilitating or fatal are significantly underestimated.

However, this unmet need represents a burgeoning opportunity for a new generation of therapeutics. The range of conditions requiring new treatments vary from minor symptoms to completely debilitating and even fatal diseases such as multiple sclerosis and Parkinsons disease. New understandings of genetics are promising early identification of sufferers for conditions caused by inborn errors of metabolism, and although many of these disorders are rare, and may qualify as "orphan diseases" under current law, many share similar underlying mechanisms, opening the possibility of expanded markets for these new treatments.

Until the 1990s, the vast majority of therapeutics for neurological diseases and disorders were palliative. With the rapidly increasing understanding of the nature of the nervous system, its interactions with muscles and other organs, and the cell biology of nerve cells, newer therapeutics are addressing root causes of neurological problems. Small biopharmaceutical companies are leading the way in advances in modern neurotherapeutics. The number of such companies, focused on neurotherapeutics, has increased significantly in the past five years and may be expected to increase further during the near term.

Kalorama’s new study looks at the worldwide market and market potential for drugs to treat these widely varying, but deadly similar diseases. The report covers the unmet need and commercial outlook for such conditions as:

  • CNS neoplasms
  • Movement disorders
  • Demyelinating diseases
  • Brain trauma ans stroke
  • Spinal cord injuries and diseases
  • Neuromuscular disorders
  • Peripheral neuropathies
  • Dementia disorders, such as Alzheimer’s disease

The study reviews current therapeutic approaches as well as forward-looking technologies, such as biological therapy, immunotherapy, and gene therapy. The study also provides a complete competitive and strategic analysis and overview of regulatory and clinical trends.


Press Release

Unmet Need and Research Innovation Drive $70+ Billion Neurotherapeutics Market

New York, July 30, 2002 /PR Newswire — Unmet need and ballooning incidence are teaming up to create huge market potential in neurological drugs, according to a new market study released today from Kalorama Information. The world market stands at $70 billion in 2002, according to the study, but steady growth in demand and product introduction will result in markets in excess of $88 billion by 2010.

The study, entitled The World Market for Neurotherapeutic Drugs, revealed several surprising findings. For example, while neurological cancer presents the largest defined segment of neurotherapeutics at the moment, the largest area of opportunity is that for peripheral neuropathies, which has been hindered in its development by lack of definition and failure to diagnose. The market potential for pharmaceuticals in the treatment of peripheral neuropathies represents $15 billion in the seven major world healthcare markets. This market potential is growing at the compound annual rate of 6.3%.

"The status of the market in terms of revenues is misleading of the potential market as a whole," points out Kenneth Krul, Ph.D., the author of the report. "It does not allow for the understanding of the potential of unmet need. The vast majority of current drugs are merely palliative; hence, the current market does not reflect the true potential of the neurological therapeutics markets."

The study thoroughly reviews market potential, research initiatives, and product commercialization across the entire spectrum of non-psychiatric neurological disease, including Alzheimer’s disease, amyotrophic lateral sclerosis, brain and spinal cord injury, cognition disorders, epilepsy, insomnia, multiple sclerosis, neurological cancers, Parkinson’s disease, peripheral neuropathy, and stroke. The study encompasses the top seven world markets: the United States, France, Germany, Italy, Japan, Spain, and the United Kingdom.

About Kalorama Information
Kalorama Information, an imprint of MarketResearch.com, supplies the latest in market research for the life sciences. For more information visit us at www.KaloramaInformation.com or contact Steven Heffner at 212-807-2634 or sheffner@kaloramainformation.com.

About MarketResearch.com
MarketResearch.com is the leading provider of global market intelligence products and services. With over 50,000 research publications from 350 research publishers, they offer instant online access to the world’s most extensive database of expert insights on global industries. Updated daily. For more information, contact Kim Bolus at 212-807-2655 or kbolus@marketresearch.com.

  • Executive Summary
    • Background
    • Scope And Methodology
      • Size And Growth Of Market
        • Table Estimated Market Sizes For The Top Five Applications Segments For Neurotherapeutics In The Major World Healthcare Markets: 2001-2009
        • Table Estimated Market Sizes For The Geographic Segments For Neurotherapeutics In The Major World Healthcare Markets 2001-2009
    • Market Trends
  • Overview Of Neurologic Diseases And Disorders
    • Background
      • History
      • Neurologic Examination
      • Diagnostic Procedures
    • Pathophysiology
      • Table Neurologic Diseases And Disorders As Classified By The United States National Institute Of Neurological Disorders And Stroke 2002 Part 1
      • Table Neurologic Diseases And Disorders As Classified By The United States National Institute Of Neurological Disorders And Stroke 2002 Part 2
      • Peripheral Nerve And Skeletal Muscle Diseases And Disorders
      • Central Nervous System Diseases And Disorders
        • Table Classification Of Diseases And Disorders Of Peripheral Nerve And Skeletal Muscle
        • Table Classification Of Diseases And Disorders Of The Central Nervous System
    • Key Neurologic Diseases And Disorders
      • Alzheimer's Disease
      • Amyotrophic Lateral Sclerosis
      • Cerebral Aneurysm
      • Ataxia Telangiectasia
      • Traumatic Brain Injury
      • Brain And Spinal Tumors
      • Carpal Tunnel Syndrome
      • Cerebral Arteriosclerosis
      • Cerebral Palsy
      • Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)
      • Creutzfeldt-Jakob Disease
      • Cushing's Syndrome
      • Cytomegalic Inclusion Body Disease
      • Dermatomyositis
      • Diabetic Neuropathy
      • Encephalitis And Meningitis
      • Epilepsy
      • Fabry's Disease
      • Gaucher's Disease
      • Guillain-Barre Syndrome
      • Huntington's Disease
      • Lesch-Nyhan Syndrome
      • Neurologic Sequelae Of Lyme Disease
      • Motor Neuron Diseases
      • Multi-Infarct Dementia
      • Multiple Sclerosis
      • Muscular Dystrophy
      • Myasthenia Gravis
      • Myopathy
      • Neurofibromatosis
      • Neurologic Manifestations Of Aids
      • Parkinson's Disease
      • Peripheral Neuropathy
      • Polymyositis
      • Shingles
      • Sjogren's Syndrome
      • Spinal Cord Injury
      • Stroke
      • Tay-Sachs Disease
      • Tourette Syndrome
      • Tremor
      • Wilson's Disease
  • Treatment Of Neurologic Diseases And Disorders
    • Demyelinating Diseases
      • Table Comparison Of Modern Drugs For The Treatment Of Relapsing-Remitting Multiple Sclerosis
      • Relapsing-Remitting Multiple Sclerosis
      • Secondary-Progressive Multiple Sclerosis
      • Other Forms Of Multiples Sclerosis
      • Other Demyelinating Diseases
    • Movement Disorders
      • Table Commonly Used Drugs For The Treatment Of Movement Disorders
      • Parkinson's Disease
      • Dystonia
      • Essential Tremor
      • Tic Disorders
    • Neuromuscular Junction Disorders
      • Myasthenia Gravis
        • Table Commonly Used Drugs For The Treatment Of Myasthenia Gravis And Neuromuscular Junction Disorders
    • Epilepsy
      • Pharmacologic Approaches
        • Table Commonly Used Epilepsy Drugs
      • Surgical Approaches
    • Viral Infections Of The Nervous System
      • Table Major Antiviral Drugs Used To Treat Central Nervous System Infections
      • Viral Encephalitis
      • Acute Meningitis
        • Table Antiretroviral Drugs
      • Human Immunodeficiency Virus (Hiv) Infection
      • Human T-Cell Lymphotropic Virus 1 (Htlv-1) Infection
      • Progressive Multifocal Leukoencephalopathy
      • Cytomegalovirus Infection
      • Varicella-Zoster Virus Infection
    • Cancer
      • Table Therapies For Key Neurologic Cancers Part 1
      • Table Therapies For Key Neurologic Cancers Part 2
    • Stroke
    • Alzheimer's Disease
      • Antipsychotics
      • Anxiolytics
      • Antidepressants
      • Anticonvulsants
  • Progress And Promise In Therapeutics Development
    • Genetics And Neurogenomics
      • Table Known Genetic Alternation In Neurologic Neoplasms
    • Neural Implant Technologies
    • Miscellaneous Advances
      • Vascular Endothelial Growth Factor (Vegf)
      • Minocycline
      • Stroke And Apoptosis
    • Clinical Trial Activity
      • Table Active Clinical Trials Involving Alzheimer's Disease And Dementia
      • Table Active Clinical Trials Involving Amyotrophic Lateral Sclerosis
      • Table Active Clinical Trials Involving Neurologic Cancers Part 1
      • Table Active Clinical Trials Involving Neurologic Cancers Part 2
      • Table Active Clinical Trials Involving Neurologic Cancers Part 3
      • Table Active Clinical Trials Involving Neurologic Cancers Part 4
      • Table Active Clinical Trials Involving Neurologic Cancers Part 5
      • Table Active Clinical Trials Involving Neurologic Cancers Part 6
      • Table Active Clinical Trials Involving Neurologic Cancers Part 7
      • Table Active Clinical Trials Involving Neurologic Cancers Part 8
      • Table Active Clinical Trials Involving Neurologic Cancers Part 9
      • Table Active Clinical Trials Involving Neurologic Cancers Part 10
      • Table Active Clinical Trials Involving Neurologic Cancers Part 11
      • Table Active Clinical Trials Involving Neurologic Cancers Part 12
      • Table Active Clinical Trials Involving Neurologic Cancers Part 13
      • Table Active Clinical Trials Involving Neurologic Cancers Part 14
      • Table Active Clinical Trials Involving Neurologic Cancers Part 15
      • Table Active Clinical Trials Involving Cerebral Palsy
      • Table Active Clinical Trials Involving Epilepsy
      • Table Active Clinical Trials Involving Genetic Factors Associated With Neurologic Diseases And Disorders Part 1
      • Table Active Clinical Trials Involving Genetic Factors Associated With Neurologic Diseases And Disorders Part 2
      • Table Active Clinical Trials Involving Genetic Factors Associated With Neurologic Diseases And Disorders Part 3
      • Table Active Clinical Trials Involving Genetic Factors Associated With Neurologic Diseases And Disorders Part 4
      • Table Active Clinical Trials Involving Huntington's Disease (Chorea)
      • Table Active Clinical Trials Involving Neurologic Infections (Primary And Secondary) Part 1
      • Table Active Clinical Trials Involving Neurologic Infections (Primary And Secondary) Part 2
      • Table Active Clinical Trials Involving Motor And Muscular Dysfunction Including Muscular Dystrophy Part 1
      • Table Active Clinical Trials Involving Motor And Muscular Dysfunction Including Muscular Dystrophy Part 2
      • Table Active Clinical Trials Involving Motor And Muscular Dysfunction Including Muscular Dystrophy Part 3
      • Table Active Clinical Trials Involving Motor And Muscular Dysfunction Including Muscular Dystrophy Part 4
      • Table Active Clinical Trials Involving Multiple Sclerosis Part 1
      • Table Active Clinical Trials Involving Multiple Sclerosis Part 2
      • Table Active Clinical Trials Involving Neurologic Pain Part 1
      • Table Active Clinical Trials Involving Neurologic Pain Part 2
      • Table Active Clinical Trials Involving Neurologic Pain Part 3
      • Table Active Clinical Trials Involving Parkinson's Disease Part 1
      • Table Active Clinical Trials Involving Parkinson's Disease Part 2
      • Table Active Clinical Trials Involving Peripheral Neuropathies
      • Table Active Clinical Trials Involving Sensory Dysfunction
      • Table Active Clinical Trials Involving Stroke Part 1
      • Table Active Clinical Trials Involving Stroke Part 2
      • Table Active Clinical Trials Involving Brain And Spinal Cord Trauma
      • Table Active Clinical Trials Involving Miscellaneous Neurologic Conditions Part 1
      • Table Active Clinical Trials Involving Miscellaneous Neurologic Conditions Part 2
      • Table Active Clinical Trials Involving Miscellaneous Neurologic Conditions Part 3
  • World Market Analysis
    • Background
    • The Markets By Geography
      • Table The Potential For Neurotherapeutics In The Seven Major World Healthcare Markets, 2001-2010
      • The United States
        • Table The Potential For Neurotherapeutics In The United States By Application, 2001-2010
      • France
        • Table The Potential For Neurotherapeutics In France By Application, 2001-2010
      • Germany
        • Table The Potential For Neurotherapeutics In Germany By Application, 2001-2010
      • Italy
        • Table The Potential For Neurotherapeutics In Italy By Application, 2001-2010
      • Spain
        • Table The Potential For Neurotherapeutics In Spain By Application, 2001-2010
      • United Kingdom
        • Table The Potential For Neurotherapeutics In The United Kingdom By Application, 2001-2010
      • Japan
        • Table The Potential For Neurotherapeutics In Japan By Application, 2001-2010
    • The Market By Applications
      • Table The Potential For Neurotherapeutics In The Major World Healthcare Markets By Application 2001-2010
      • Alzheimer's Disease And Other Dementias
        • Table The Potential For Alzheimer's Disease/Dementia Therapeutics In The Major World Healthcare Markets 2001-2010
      • Secondary Amyloidosis
        • Table The Potential For Secondary Amyloidosis Therapeutics In The Major World Healthcare Markets 2001-2010
      • Brain/Neurologic Cancers
        • Table The Potential For Brain And Neurologic Cancer Therapeutics In The Major World Healthcare Markets 2001-2010
      • Cognition Disorders
        • Table The Potential For Cognition Therapeutics In The Major World Healthcare Markets 2001-2010
      • Epilepsy
        • Table The Potential For Epilepsy Therapeutics In The Major World Healthcare Markets 2001-2010
      • Insomnia
        • Table The Potential For Insomnia Therapeutics In The Major World Healthcare Markets 2001-2010
      • Multiple Sclerosis
        • Table The Potential For Multiple Sclerosis Therapeutics In The Major World Healthcare Markets 2001-2010
      • Parkinson's Disease
        • Table The Potential For Parkinson's Disease Therapeutics In The Major World Healthcare Markets 2001-2010
      • Peripheral Neuropathy
        • Table The Potential For Peripheral Neuropathy Therapeutics In The Major World Healthcare Markets 2001-2010
      • Spinal Cord Injury (Sci)
        • Table The Potential For Spinal Cord Injury Therapeutics In The Major World Healthcare Markets 2001-2010
      • Stroke
        • Table The Potential For Stroke Therapeutics In The Major World Healthcare Markets 2001-2010
      • Traumatic Brain Injury
        • Table The Potential For Traumatic Brain Injury Therapeutics In The Major World Healthcare Markets 2001-2010
  • Company Profiles
    • Axonyx
    • Boston Life Sciences, Inc.
      • Troponin
      • Inosine And Axogenesis Factor 1 (Af-1)
    • Bls-602
    • C-Maf
      • Fluoratec Imaging Agent
    • Centaur Pharmaceuticals, Inc.
    • Cephalon, Inc.
    • Cognetix Incorporated
    • Cortex Pharmaceuticals, Inc.
    • Curis, Inc.
    • Diacrin
    • D-Pharm Ltd.
    • Elan Corporation Plc
    • Genset Sa
    • Guilford Pharmaceuticals Inc.
    • Mitokor Inc.
    • Neotherapeutics, Inc.
      • Neotrofin
      • Ait-034
      • Neo-339
      • Neoquin
      • Satraplatin
      • Elsamitrucin
    • Nps Pharmaceuticals, Inc.
    • Neurobiological Technologies, Inc.
    • Neurochem, Inc.
    • Neurocrine Biosciences, Inc.
      • Indiplon
      • Ngi-3001
      • Nbi-6023
      • Nbi-5788
      • Nbi-34041
      • Gnrh
    • Neurogen Corporation
      • Cognition Disorders (Gaba)
      • Inflammation And Autoimmune Disorders (C5A)
      • Insomnia (Gaba)
      • Depression And Stress (Crf1)
      • Pain (Vr-1)
      • Obesity (Mch)
    • Pharmos Corporation
    • Shire Pharmaceuticals Group Plc
      • Pain Treatment
      • Epilepsy Treatment
      • Parkinson's Disease Treatment
    • Stem Cells Inc.
    • Titan Pharmaceuticals, Inc.
  • Conclusions And Strategic Implications
    • First Conclusion
      • Implications
    • Second Conclusion
      • Implications
    • Third Conclusion
      • Implications
    • Fourth Conclusion
      • Implications
    • Fifth Conclusion
      • Implications
    • Sixth Conclusion
      • Implications
    • Seventh Conclusion
      • Implications
  • Glossary
  • Company Directory

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report